Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.

Warnock, David G; Wallace, Eric L

Warnock, David G; Wallace, Eric L.

Affiliation

Warnock DG; Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA dwarnock@uab.edu.
Wallace EL; Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

J Med Genet ; 61(6): 534-535, 2024 May 21.

Article in En | MEDLINE | ID: mdl-38589225

Subject(s)
Key words

Fabry Disease

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Proteins / Fabry Disease / Alpha-Galactosidase / Isoenzymes Limits: Humans Language: En Journal: J Med Genet Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google